Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Shapiro

MOHS-Micrographic Surgery Brooklyn, NY Medical Doctor

NPI 1740381516 CMS profile 351139

2148 Ocean Ave Fl 5, Brooklyn, NY 11229

Open in the dashboard

General payments

$4,276

212 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Shapiro of Brooklyn, NY is reported in the CMS Open Payments database as having received $4,276 across 212 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $234 10
2024 General $340 14
2023 General $289 13
2022 General $504 19
2021 General $565 25
2020 General $734 43
2019 General $1,609 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Shapiro
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Michael Shapiro were reported at $234. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Michael Shapiro MOHS-Micrographic Surgery median Middle half National median
2019 $1,609 $316 $106–$785 $163
2020 $734 $162 $68–$412 $114
2021 $565 $243 $87–$654 $132
2022 $504 $300 $102–$887 $149
2023 $289 $364 $125–$1,010 $160
2024 $340 $445 $142–$1,108 $164
2025 $234 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $779 45 payments
  2. AbbVie, Inc. $682 33 payments
  3. Regeneron Healthcare Solutions, Inc. $539 23 payments
  4. E.R. Squibb & Sons, L.L.C. $260 13 payments
  5. Biofrontera Inc. $170 9 payments
  6. LEO Pharma Inc. $153 2 payments
  7. Lilly USA, LLC $145 7 payments
  8. Genzyme Corporation $138 6 payments
  9. Dermira, Inc. $118 5 payments
  10. Pfizer Inc. $110 6 payments
  11. Other $1,183 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,107 210 payments
  2. Education $98 1 payment
  3. Grant $70 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT $511 22 payments
  2. COSENTYX Dermatology $393 23 payments
  3. HUMIRA $369 22 payments
  4. SKYRIZI $318 15 payments
  5. COSENTYX Immunology $217 14 payments
  6. SOTYKTU $217 11 payments
  7. XEPI $170 9 payments
  8. ADBRY $153 2 payments
  9. TALTZ $145 7 payments
  10. COSENTYX Dermatology $115 5 payments
  11. Other $2,212 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,952

Median for Dermatology: 534

Drug cost

$203,365

Median for Dermatology: $67,151

Branded share of claims

7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 32 $149,533
Tacrolimus Generic 203 $22,408
Mycophenolate Mofetil Generic 35 $5,648
Ivermectin Generic 29 $5,374
Ketoconazole Generic 204 $3,905
Fluocinonide Generic 84 $3,139
Triamcinolone Acetonide Generic 323 $1,814
Doxycycline Hyclate Generic 520 $1,638
Clindamycin Phosphate Generic 44 $1,631
Halobetasol Propionate Generic 35 $1,304

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$1,282,139

Of which drugs: $652

Medicare patients

1,283

Average age 78

Services billed

9,253

701 women, 582 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 59%
Ischemic heart disease 51%
Depression 31%
Heart failure 27%
Chronic kidney disease 24%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 38 84 $64

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $68
$68 — —
SKYRIZI
  • AbbVie, Inc. $49
$49 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $42
$42 — —
YCANTH
  • VERRICA PHARMACEUTICALS INC. $22
$22 — —
RINVOQ
  • AbbVie, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record